引用文本：陈健聪, 赖佳明. 胰腺癌2025年研究进展盘点——从年度热词看胰腺癌治疗的突破与反思[J/CD]. 消化肿瘤杂志（电子版）, 2026, 18(1): 69-74.

作者：陈健聪，赖佳明

单位：中山大学附属第一医院胆胰外科，广东 广州 510080

Authors：Chen Jiancong, Lai Jiaming

Unit：Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China

摘要：

胰腺癌作为“癌中之王”，其诊疗一直面临巨大挑战。2025年胰腺癌领域涌现出诸多研究热点，既有令人鼓舞的突破性进展，也有发人深省的阴性结果。本文通过解析2025年度胰腺癌三大临床热词——Claudin18.2抗体联合化学治疗的挫折、肿瘤电场治疗的突破以及KRAS抑制剂的曙光，系统回顾了当前晚期胰腺癌治疗的研究现状。文章深入剖析了阳性与阴性研究结果背后的科学内涵，总结了临床实践中容易被忽视的关键细节，并展望了未来研究方向。综合分析提示，胰腺癌治疗需要构建多学科协作的精准诊疗体系，在基础研究突破与现有治疗手段优化之间实现双轮驱动，从而为患者带来真正的临床获益。

关键词：胰腺癌；Claudin18.2；肿瘤电场治疗；KRAS抑制剂；精准治疗；多学科协作

Abstract：

Pancreatic cancer, known as the "king of cancers", continues to pose tremendous challenges in diagnosis and treatment. The year 2025 has witnessed numerous research hotspots in the field of pancreatic cancer, including both encouraging breakthroughs and thought-provoking negative results. This article systematically examines the current research status of advanced pancreatic cancer treatment by analyzing three major clinical keywords of 2025: the setback of Claudin18.2 antibody combined with chemotherapy, the breakthrough of tumor treating fields (TTFields), and the promise of KRAS inhibitors. The article provides in-depth analysis of the scientific implications behind both positive and negative research findings, summarizes key clinical details that are often overlooked in practice, and outlines future research directions. Comprehensive analysis suggests that pancreatic cancer treatment requires the establishment of a multidisciplinary precision therapy system, achieving dual-wheel drive between breakthroughs in basic research and optimization of existing therapeutic approaches, in order to bring genuine clinical benefits to patients.

Key words：Pancreatic cancer; Claudin18.2; Tumor treating fields; KRAS inhibitors; Precision therapy; Multidisciplinary collaboration

注：网络优先发布